AIDS-related Kaposi sarcoma (KS)
HIV malignancy · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
HHV-8 (KSHV)-driven vascular tumour; AIDS-defining. Cutaneous disease is most common (lower limbs, face/nose, oral mucosa, genitalia) but it can involve oral cavity, GI tract and lungs. Incidence is highest in the first 6 months of ART (IRIS unmasking). ED role: recognise, biopsy to exclude mimics, avoid steroids, start/continue ART, manage complications.
Red flags
- Haemoptysis / dyspnoea / respiratory failure (pulmonary KS)
- GI bleeding, obstruction or severe abdominal pain
- Airway-threatening oral/laryngeal lesions
- Rapidly progressive or atypical lesions (exclude bacillary angiomatosis)
- KICS features: fever, oedema, high tumour burden (poor prognosis)
Assessment
Differential diagnosis
- Bacillary angiomatosis (Bartonella - treatable; must exclude)
- Purpura/haematoma
- Angioma / pyogenic granuloma
- Dermatofibroma / naevi
- Extrapulmonary P. jirovecii (can mimic KS)
- Cutaneous lymphoma / melanoma
Investigations
- Skin biopsy to confirm (essential for atypical or rapidly progressive lesions to exclude bacillary angiomatosis)
- CD4 count + HIV viral load
- FBC
- If respiratory symptoms: CXR (nodular/interstitial infiltrates, effusion, hilar/mediastinal adenopathy)
- If GI symptoms: refer for endoscopy (hemorrhagic nodules)
- Assess for visceral involvement (oral, GI, pulmonary)
Management
- Recognise violaceous/pink-red-purple-brown non-blanching lesions, often elliptical along skin tension lines
- Biopsy to confirm and exclude bacillary angiomatosis (curable)
- Assess for visceral disease (oral cavity, GI, lungs)
- Avoid systemic corticosteroids - they induce/exacerbate KS
- Start/optimise ART (cornerstone of treatment)
- Refer oncology for staging and systemic chemotherapy if advanced/visceral/pulmonary
- Treat complications (bleeding, airway compromise, lymphoedema)
Drugs & doses
Antiretroviral therapy (ART) is the cornerstone - start/optimise via HIV team
AVOID systemic corticosteroids - associated with KS induction/exacerbation
Systemic chemotherapy (e.g. liposomal anthracyclines, paclitaxel) for advanced/visceral/pulmonary KS - oncology-directed, NOT ED-initiated (specific regimens/doses are in the KS staging & treatment topic, not this source)
If bacillary angiomatosis cannot be excluded, treat empirically for Bartonella pending biopsy (specialist; agent not specified in source)
Disposition
Most cutaneous KS -> outpatient HIV/oncology referral + ART. Admit for pulmonary KS with respiratory compromise, GI bleeding, airway threat, or KICS.
Complications & pitfalls
- Pulmonary KS (respiratory failure, haemoptysis)
- GI bleeding / obstruction
- Disfiguring lymphoedema
- KSHV inflammatory cytokine syndrome (KICS; median survival ~13.6 months)
- IRIS flare in first 6 months of ART
- Secondary infection of ulcerated lesions
Exam pearls
- Always biopsy atypical/rapidly-progressive lesions to exclude Bartonella bacillary angiomatosis (curable with antibiotics)
- Corticosteroids and opportunistic infections can trigger/worsen KS - avoid steroids
- KS can flare within the first 6 months of ART (IRIS)
- Visceral disease (oral/GI/lung) is often asymptomatic initially
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.